Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

[Noninferiority trials: several simple principles].

Eric Vicaut1, Michel Cucherat

  • 1Unité de Recherche Clinique, Hôpital Fernand Widal, Paris. eric.vicaut@lrb.ap-hop-paris.fr

Presse Medicale (Paris, France : 1983)
|February 10, 2007
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

PErsistence and Safety of Subcutaneous Infliximab 1 Year After Switch From Intravenous Route in IBD Patients in REMission.

Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association·2025
Same author

Iloprost for the Treatment of Severe Septic Shock with Persistent Hypoperfusion: A Double-Blind, Randomized Controlled Trial.

American journal of respiratory and critical care medicine·2025
Same author

Eliciting the Impact of Metformin and Statins on Prostate Cancer Outcomes from a Real-life National Database Analysis.

European urology oncology·2025
Same author

Twice-a-day administration of aspirin in patients with diabetes mellitus or aspirin resistance after acute coronary syndrome: Rationale and design of the randomized ANDAMAN trial.

American heart journal·2025
Same author

Design of the OverCool study: Lung-conservative liquid ventilation for the induction of Ultra-Rapid Cooling after Cardiac Arrest (OverCool).

Resuscitation plus·2025
Same author

Transcranial ultrasound localization microscopy in moyamoya patients using a clinical ultrasound system.

Theranostics·2025
Same journal

Artificial Intelligence in medical research and publishing: progress, risks, and future perspectives.

Presse medicale (Paris, France : 1983)·2026
Same journal

Ethical, legal, and regulatory challenges in AI-based healthcare tools.

Presse medicale (Paris, France : 1983)·2026
Same journal

Decision-making for clinicians.

Presse medicale (Paris, France : 1983)·2026
Same journal

Beyond one-size-fits-all: Personalising health communication to drive real behaviour change.

Presse medicale (Paris, France : 1983)·2026
Same journal

Metacognition and post-decisional processing in clinical decision-making.

Presse medicale (Paris, France : 1983)·2026
Same journal

Fast-and-frugal decision trees for clinicians.

Presse medicale (Paris, France : 1983)·2026
See all related articles

Noninferiority trials demonstrate new treatments are not worse than existing ones. However, they don't prove equivalence and require additional benefits like improved tolerance for true therapeutic progress.

Area of Science:

  • Clinical Trials
  • Pharmaceutical Research
  • Biostatistics

Context:

  • Noninferiority trials are crucial for evaluating new medical treatments against established standards.
  • These trials assess if a new treatment's efficacy is not unacceptably worse than a reference treatment.

Purpose:

  • To explain the interpretation and limitations of noninferiority trial results.
  • To clarify that noninferiority does not equate to therapeutic equivalence or progress.

Summary:

  • Noninferiority trials can conclude a new treatment is not worse than a reference, within a predefined margin.
  • They cannot establish strict efficacy equivalence; a possibility of inferiority within the margin remains.
  • Therapeutic advancement requires noninferiority plus advantages like better tolerance or usability.

Related Experiment Videos

Impact:

  • Informs clinicians and researchers on the nuanced interpretation of noninferiority trial outcomes.
  • Guides decision-making in adopting new treatments by emphasizing the need for demonstrable advantages beyond noninferiority.
  • Highlights the clinical nature of setting noninferiority margins, focusing on acceptable efficacy loss.